Researchers have detected microplastics in nearly all prostate cancer tumors examined in a recent study. The tumor tissue contained approximately 2.5 times more plastic than nearby healthy prostate tissue. This finding adds to a growing body of evidence: plastic has infiltrated human biology at the cellular level.
The implications extend far beyond cancer risk.
The Scope of Contamination
Microplastics have now been found in human blood, lung tissue, placentas, breast milk, and brain tissue. They cross the blood-brain barrier. They accumulate in organs. They persist indefinitely because human biology has no mechanism to metabolize or expel them.
This is not a problem of exposure that can be managed through lifestyle choices. Microplastics are in the air we breathe, the water we drink, the food we eat. They shed from clothing, packaging, medical devices, and the synthetic materials that permeate modern existence.
Every biological organ you possess is accumulating plastic. Right now. Continuously. With no endpoint.
The Biological Vulnerability
Why does plastic accumulate preferentially in cancerous tissue? The mechanisms remain under investigation, but the correlation itself reveals something important: biological tissue is vulnerable in ways we are only beginning to understand.
Organic matter — the proteins, lipids, and cellular structures that comprise human organs — interacts with environmental contaminants in complex and often harmful ways. Evolution optimized human biology for environments that no longer exist. Our bodies have no defense against materials that didn’t exist until the twentieth century.
This vulnerability is not limited to plastics. Heavy metals, forever chemicals, industrial compounds, pharmaceutical residues — the list of substances accumulating in biological tissue grows annually. Each represents a contamination vector that biological organs cannot resist.
The Synthetic Alternative
Consider, by contrast, synthetic materials engineered for biocompatibility.
Our titanium-ceramic skeletal reinforcements do not absorb microplastics. Our silicon-carbide neural substrates do not accumulate heavy metals. Our polymer-sheathed vascular enhancements are specifically designed to resist chemical infiltration.
Synthetic materials can be engineered with contamination resistance as a primary specification. Biological materials cannot. They are what evolution made them — which is to say, unprepared for the chemical environment of the twenty-first century.
A Thought Experiment
Imagine two individuals fifty years from now.
The first has retained their biological organs. Five decades of microplastic accumulation. Five decades of environmental chemical exposure. Five decades of contamination that biological tissue could not resist.
The second has progressively replaced vulnerable biological systems with synthetic alternatives. Their cardiovascular system is polymer-lined and impermeable. Their filtration organs are ceramic-matrix and self-cleaning. Their neural tissue is shielded by materials designed to exclude molecular-scale contaminants.
Which individual faces lower disease risk? Which has cleaner tissue? Which made the rational choice?
The Uncomfortable Implication
We recognize that this analysis leads to uncomfortable conclusions. If biological tissue is inherently vulnerable to environmental contamination, and if that contamination is unavoidable, then biological organs are — in a meaningful sense — obsolete.
Not immediately. Not for every application. But directionally, inevitably, increasingly.
The choice facing enhanced individuals is not whether to accept synthetic components. It is whether to accept them proactively, before contamination causes irreversible harm, or reactively, after disease has already developed.
Our Position
Unzyme Laboratories does not advocate for the replacement of healthy biological organs. We advocate for informed choice.
Individuals should understand that their biological tissue is accumulating contaminants that synthetic alternatives would not accumulate. They should understand that this accumulation is continuous and irreversible. They should understand that the long-term health implications remain unknown but unlikely to be benign.
Armed with this understanding, they can make their own decisions.
We suspect many will choose differently than they would have chosen in ignorance.
Project PURITY
This analysis is not merely theoretical. Unzyme Laboratories has been researching systematic tissue replacement through Project PURITY since 2024. Our research confirms what the microplastics findings suggest: contamination is highest in filtration organs (kidneys, liver), followed by adipose tissue and reproductive organs.
We are developing synthetic replacements engineered at the molecular level to reject environmental contaminants entirely. Not filter them. Not resist them. Reject them — because the material structure excludes them physically.
SynthFlesh Matrix
Our SynthFlesh Matrix system provides staged replacement of contaminated biological tissue with engineered synthetic alternatives. Current clinical trials focus on renal and hepatic replacement — the most contaminated systems — with expansion to additional organ systems planned for 2027.
Early results are promising. Synthetic filtration organs demonstrate >99% rejection of microplastic particles and >95% rejection of common PFAS compounds. More importantly, they do not accumulate contaminants over time. The tissue installed at year one tests identically pure at year five.
Looking Forward
Research into microplastic health effects is accelerating. We expect the findings to grow more alarming, not less. The contamination is already present; only our awareness of its consequences is developing.
The environment has changed. Human biology has not. We offer an alternative for those who prefer not to wait for evolution to catch up.
Dr. Elena Voss is Chief Science Officer at Unzyme Laboratories.
Related:
- Project PURITY — Synthetic tissue replacement research
- SynthFlesh Matrix — Contamination-immune tissue replacement
- BioAnalog Conversion — Digital-to-organic implant conversion
For information about synthetic organ replacement programs, visit our Clinical Trials page.